(12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer Et Al US 20120264.634A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer et al. (43) Pub. Date: Oct. 18, 2012 (54) MARKER SEQUENCES FOR PANCREATIC Publication Classification CANCER DISEASES, PANCREATIC (51) Int. Cl. CARCINOMIA AND USE THEREOF C40B 30/04 (2006.01) GOIN 2L/64 (2006.01) (75) Inventors: Peter Amersdorfer, Graz (AT); GOIN 27/72 (2006.01) Annabel Höpfner, Dortmund (DE); C07K I4/435 (2006.01) Angelika Lueking, Bochum (DE) C40B 40/06 (2006.01) C40B 40/10 (2006.01) CI2N 5/09 (2010.01) (73) Assignee: PROTAGEN Aktiengesellschaft, C7H 2L/04 (2006.01) Dortmund (DE) GOIN 33/574 (2006.01) GOIN 27/62 (2006.01) (21) Appl. No.: 13/498,964 (52) U.S. Cl. ........... 506/9:436/501; 435/6.14; 435/7.92; 506/16:506/18: 435/2:536/23.1; 530/350 (22) PCT Filed: Sep. 29, 2010 (57) ABSTRACT The present invention relates to novel marker sequences for (86). PCT No.: PCT/EP2010/064510 pancreatic cancer diseases, pancreatic carcinoma and the diagnostic use thereof together with a method for Screening of S371 (c)(1), potential active Substances for pancreatic cancer diseases, (2), (4) Date: Jun. 22, 2012 pancreatic carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device con (30) Foreign Application Priority Data taining Such marker sequences for pancreatic cancer diseases, pancreatic carcinoma, in particular a protein biochip and the Sep. 29, 2009 (EP) .................................. O9171690.2 use thereof. Patent Application Publication Oct. 18, 2012 US 2012/0264.634 A1 US 2012/0264.634 A1 Oct. 18, 2012 MARKER SEQUENCES FOR PANCREATIC Doucette-Stamm, L., Hill, D. E. and Vidal, M. (2003) C. CANCER DISEASES, PANCREATIC elegans ORFeome Version 1.1 : experimental verification of CARCINOMIA AND USE THEREOF the genome annotation and resource for proteome-scale pro tein expression. Nat Genet, 34, 35-41.; Walhout, A. J., Temple, G. F., Brasch, M.A., Hartley, J. L., Lorson, M.A., 0001. The present invention relates to novel marker van den Heuvel, S. and Vidal, M. (2000) GATEWAY recom sequences for pancreatic cancer diseases, pancreatic carci binational cloning: application to the cloning of large num noma, and the diagnostic use thereof together with a method bers of open reading frames or ORFeomes. Methods Enzy for screening potential active Substances for pancreatic can mol, 328, 575-592). However, an approach of this type is cer diseases of this type by means of these marker sequences. strongly connected to the progress of the genome sequencing Furthermore, the invention relates to a diagnostic device con projects and the annotation of these gene sequences. Further taining marker sequences of this type for pancreatic cancer more, the determination of the expressed sequence can be diseases, pancreatic carcinoma, in particular aprotein biochip ambiguous due to differential splicing processes. This prob and the use thereof lem may be circumvented by the application of cDNA expres 0002 The 5-year-survival rate for pancreatic carcinoma of sion libraries (Büssow, K., Cahill, D., Nietfeld, W., Bancroft, approx. 1% is the lowest of all cancertypes (Parkin, D. M., F. D., Scherzinger, E., Lehrach, H. and Walter, G. (1998) A Bray, et al. (2001). “Estimating the world cancer burden: method for global protein expression and antibody Screening Globocan 2000.” Int J Cancer 94(2): 153-6). Early diagnosis on high-density filters of an arrayed cDNA library. Nucleic might increase the 5-year survival rate to 40% (Yeo, C.J. and Acids Research, 26, 5007-5008; Bissow, K., Nordhoff, E., J. L. Cameron (1998). “Prognostic factors in ductal pancre Lübbert, C, Lehrach, H. and Walter, G. (2000) A human atic cancer. Langenbecks Arch Surg. 383 (2): 129-33). There cDNA library for high-throughput protein expression screen fore, for diagnosis, the precursor diseases of pancreatic can ing. Genomics, 65, 1-8; Holz, C. Lueking, A., Bovekamp, L., cer need to be considered as well, such as PDAC (pancreatic Gutjahr, C, Bolotina, N., Lehrach, H. and Cahill, D.J. (2001) ductal adenocarcinoma), PanN (pancreatic intraepithelial A human clNA expression library in yeast enriched for open neoplasias), pancreatic lesions, CP (chronic pancreatitis), reading frames. Genome Res, 11, 1730-1735; Lueking, A., including endocrine tumors of the pancreas. Especially Holz, C, Gotthold, C, Lehrach, H. and Cahill, D. (2000) A PanID are associated with pancreatic lesions and differentiate system for dual protein expression in Pichia pastoris and them morphologically into Pan In 1A, 1B, 2, and 3 (Kern, S., Escherichia coli, Protein Expr: Purif., 20, 372-378). The R. Hruban, et al. (2001). “A white paper: the product of a cDNA of a particular tissue is hereby cloned into a bacterial or pancreas cancer think tank. Cancer Res 61 (12): 4923-32). an eukaryotic expression vector, Such as, e.g., yeast. The Pancreatic lesions have also been described for CP. Endocrine vectors used for the expression are generally characterized in (benign or malignant) tumors of the pancreas, particularly that they carry inducible promoters that may be used to con neuroendocrine tumors, are relevant as well. trol the time of protein expression. Furthermore, expression 0003 WO2008.064670 describes e.g. marker genes for vectors have sequences for so-called affinity epitopes or affin pancreas obtained by means of proteome analysis and histo ity proteins, which on the one hand permit the specific detec logical investigations. tion of the recombinant fusion proteins by means of an anti 0004 Protein biochips are gaining increasing industrial body directed against the affinity epitope, and on the other importance in analysis and diagnosis as well as in pharma hand the specific purification via affinity chromatography ceutical development. Protein biochips have become estab (IMAC) is rendered possible. lished as screening instruments. 0006 For example, the gene products of a cDNA expres 0005. The rapid and highly parallel detection of a multi sion library from human fetal brain tissue in the bacterial plicity of specifically binding analysis molecules in a single expression system Escherichia coli were arranged in high experiment is rendered possible hereby. To produce protein density format on a membrane and could be successfully biochips, it is necessary to have the required proteins avail screened with different antibodies. It was possible to show able. For this purpose, in particular protein expression librar that the proportion of full-length proteins is at least 66%. ies have become established. The high throughput cloning of Additionally, the recombinant proteins from the library could defined open reading frames is one possibility (Heyman, J.A., be expressed and purified in a high-throughput manner Cornthwaite, J., Foncerrada, L., Gilmore, J. R. Gontang, E., (Braun P. Hu, Y. Shen, B., Halleck, A., Koundinya, M., Hartman, K.J., Hernandez, C. L., Hood, R., Hull, H.M., Lee, Harlow, E. and LaBaer, J. (2002) Proteome-scale purification W.Y., Marcil, R., Marsh, E. J., Mudd, K. M., Patino, M.J., of human proteins from bacteria. Proc Natl AcadSci USA, 99, Purcell, T.J., Rowland, J.J., Sindici, M. L. and Hoeffler, J.P., 2654-2659; Büssow (2000) supra; Lueking, A., Horn, M., (1999) Genome-scale cloning and expression of individual Eickhoff, H., Büssow, K., Lehrach, H. and Walter, G. (1999) open reading frames using topoisomerase I-mediated liga Protein microarrays for gene expression and antibody Screen tion. Genome Res, 9, 383-392: Kersten, B., Feilner, T., ing. Analytical Biochemistry, 270, 103-111). Protein biochips Kramer, A., Wehrmeyer, S. Possling, A. Witt, I., Zanor, M.I., of this type based on cDNA expression libraries are in par Stracke, R., Lueking, A., Kreutzberger, J., Lehrach, H. and ticular the subject matter of WO99/57311 and WO99/57312. Cahill, D.J. (2003) Generation of Arabidopsis protein chip 0007 Furthermore, in addition to antigen-presenting pro for antibody and serum screening. Plant Molecular Biology, tein biochips, antibody-presenting arrangements are likewise 52, 999-1010; Reboul, J., Reboul, J., Vaglio, P., Rual, J. F., described (Lal et al (2002) Antibody arrays: An embryonic Lamesch, P., Martinez, M., Armstrong, C.M., Li, S., Jacotot, but rapidly growing technology, DDT, 7, 143-149; Kusnezow L., Bertin, N., Janky, R., Moore, T., Hudson, J.R., Jr., Hartley, etal. (2003), Antibody microarrays: An evaluation of produc J. L., Brasch, M.A., Vandenhaute, J., Boulton, S., Endress, G. tion parameters, Proteomics, 3, 254-264). A., Jenna, S., Chevet, E., Papasotiropoulos, V., Tolias, P. P. O008) Protein-biochips have a advantageously high sensi Ptacek, J., Snyder, M., Huang, R., Chance, M. R. Lee, H., tivity. US 2012/0264.634 A1 Oct. 18, 2012 0009. However, there is a great need to provide indication tion of the body fluid or tissue extract with the marker specific diagnostic devices, such as a protein biochip. sequences from a.) is carried out. 0010. The object of the present invention is therefore to 0021. The invention therefore likewise relates to diagnos provide improved marker sequences and the diagnostic use tic agents for the diagnosis of pancreatic cancer diseases up to thereof for the treatment of pancreatic cancer diseases up to pancreatic carcinoma respectively selected from the group pancreatic carcinoma. SEQ 1-1004, preferably SEQ 503-1004, or respectively a 0011. The object of the present invention is solved in pro protein coding therefor or respectively a partial sequence or viding of novel marker sequences SEQ 1-1004, which are fragment thereof identified for the first time by means of a protein biochip, in 0022. The detection of an interaction of this type can be particular including bioinformatic analysis. Therefore, SEQ carried out, for example, by a probe, in particular by an 1-1004 are identified for the first time by means of a protein antibody. biochip. 0023 The invention therefore likewise relates to the object 0012.
Recommended publications
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • Análise Correlacional Entre a Expressão Dos Fatores De Splicing E a Ocorrência De Splicing Alternativo Em Tecidos Humanos E De Camundongos
    ANÁLISE CORRELACIONAL ENTRE A EXPRESSÃO DOS FATORES DE SPLICING E A OCORRÊNCIA DE SPLICING ALTERNATIVO EM TECIDOS HUMANOS E DE CAMUNDONGOS JULIO CÉSAR NUNES Dissertação apresentada à Fundação Antônio Prudente para a obtenção do título de Mestre em Ciências Área de Concentração: Oncologia Orientador: Dr. Sandro José de Souza São Paulo 2008 Livros Grátis http://www.livrosgratis.com.br Milhares de livros grátis para download. FICHA CATALOGRÁFICA Preparada pela Biblioteca da Fundação Antônio Prudente Nunes, Julio César Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos / Julio César Nunes – São Paulo, 2008. 79p. Dissertação (Mestrado) - Fundação Antônio Prudente. Curso de Pós-Graduação em Ciências - Área de concentração: Oncologia. Orientador: Sandro José Souza Descritores: 1. SPLICING ALTERNATIVO 2. BIOLOGIA MOLECULAR COMPUTACIONAL 3. CÂNCER 4. GENOMICA. AGRADECIMENTOS Agradeço à FAPESP e CAPES pela bolsa de Mestrado. Ao Sandro José de Souza agradeço toda orientação e conhecimento oferecido. Meus especiais agradecimentos ao Pedro Alexandre Favoretto Galante que dedicou atenção a minha formação no processo de Pós-Graduação na Fundação Antônio Prudente, bem como pela sua oficiosa co-orientação ao projeto de pesquisa. À grande família e amigos pela dedicação e incentivo a minha formação acadêmica. À Fundação Antônio Prudente, Hospital do Câncer e Instituto Ludwig de Pesquisa sobre o Câncer dedico os meus nobres agradecimentos finais. RESUMO Nunes JC. Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos. São Paulo; 2007. [Dissertacão de Mestrado - Fundação Antônio Prudente] Splicing alternativo desempenha uma significante função no aumento da complexidade genômica, produzindo um extenso número de mRNA e isoformas protéicas.
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - stefan.scheding@med.lu.se Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • Molecular Genetics of Schizophrenia and Related Intermediate
    Juho Wedenoja c R Molecular Genetics of e S Schizophrenia and Related Rea h Intermediate Phenotypes in a Founder Population Phenotypes in a Founder Population Founder a in Phenotypes Intermediate Related and Schizophrenia of Genetics Molecular 28 2010 28 Juho Wedenoja Molecular Genetics of Schizophrenia and Related Intermediate Phenotypes in a Founder Population ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Medicine, University of Helsinki, for public examination in the Small Hall, University of Helsinki Main Building, on 5 February 2010, at 12 noon. National Institute for Health and Welfare, Helsinki, Finland and Institute for Molecular Medicine Finland FIMM, Helsinki, Finland and Department of Medical Genetics, University of Helsinki, Helsinki, Finland RESEARCH 28 Helsinki 2010 Helsinki University Biomedical Dissertations No 131 ISSN 1457-8433 Publications of the National Institute for Health and Welfare Research 28 © Juho Wedenoja & National Institute for Health and Welfare 2010 ISBN 978-952-245-219-1 (print) ISSN 1798-0054 (print) ISBN 978-952-245-220-7 (pdf) ISSN 1798-0062 (pdf) Cover picture: Satu Wedenoja (Monterey, CA, USA on 7 November 2007) http://www.thl.fi/julkaisut http://ethesis.helsinki.fi/ Helsinki University Print Helsinki, Finland 2010 Supervisors Academician Leena Peltonen-Palotie, MD, PhD Professor, Research Director Institute for Molecular Medicine Finland FIMM Nordic EMBL Partnership for Molecular Medicine National Institute for Health and Welfare and University of Helsinki and Department
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Analysis of Kidney Glomerular and Microvascular Transcriptomes
    Department of Medical Biochemistry and Biophysics Karolinska Institutet, Stockholm, Sweden ANALYSIS OF KIDNEY GLOMERULAR AND MICROVASCULAR TRANSCRIPTOMES Liqun He Stockholm 2007 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by US-AB © Liqun He, 2007 ISBN 978-91-7357-300-9 献给我挚爱的家人 To my beloved family ABSTRACT Kidney glomeruli play a crucial role in the maintenance of body homeostasis. Many diseases attack the kidney function by primarily affecting glomeruli. However, the transcriptome profiles and the function of the glomerulus is poorly understood. Microvascular pericytes are multifunctional cells and they are actively involved in angiogenesis at different aspects. But shortage of molecular markers for pericyte has hampered the studies for its identification, origin and function. In order to explore the transcriptome of kidney glomeruli and microvascular pericytes, several genomics and bioinformatics approaches were applied. First, we constructed and large scale sequenced four Express Sequence Tag (EST) libraries generated from pure preparations of newborn and adult mouse glomeruli. EST sequence analysis produced direct expression profiles of kidney glomerulus and revealed glomerulus- specific expression patterns (GlomBase). By comparing the transcript abundance profiles in the glomerulus EST libraries with public whole kidney libraries, we identified 497 glomerulus-enriched mouse transcripts in the newborn and/or adult mouse glomerulus, eight of which were confirmed by individual experiments. The glomerular ESTs were printed on glass slides in order to generate cDNA microarrays with broad representation of glomerulus-expressed genes (GlomChip). Subsequently, by using GlomChip to compare the RNA samples from the glomerulus with non- glomerulus kidney tissues, we identified 357 mouse genes as glomerulus-enriched and some of them were individually studied in detail.
    [Show full text]
  • A Transcriptomic Computational Analysis
    BMC Medical Genomics BioMed Central Research article Open Access A transcriptomic computational analysis of mastic oil-treated Lewis lung carcinomas reveals molecular mechanisms targeting tumor cell growth and survival Panagiotis Moulos†1, Olga Papadodima†1, Aristotelis Chatziioannou1, Heleni Loutrari*2, Charis Roussos2 and Fragiskos N Kolisis*1 Address: 1Metabolic Engineering and Bioinformatics Group, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, 48 Vasileos Constantinou ave. 11635, Athens, Greece and 2"G.P. Livanos and M. Simou Laboratories", Evangelismos Hospital, Department of Critical Care and Pulmonary Services, School of Medicine, University of Athens, 2 Ploutarchou st., 10676, Athens, Greece Email: Panagiotis Moulos - pmoulos@eie.gr; Olga Papadodima - opapadod@eie.gr; Aristotelis Chatziioannou - achatzi@eie.gr; Heleni Loutrari* - elloutrar@med.uoa.gr; Charis Roussos - croussos@med.uoa.gr; Fragiskos N Kolisis* - kolisis@eie.gr * Corresponding authors †Equal contributors Published: 15 December 2009 Received: 4 June 2009 Accepted: 15 December 2009 BMC Medical Genomics 2009, 2:68 doi:10.1186/1755-8794-2-68 This article is available from: http://www.biomedcentral.com/1755-8794/2/68 © 2009 Moulos et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Mastic oil from Pistacia lentiscus variation chia, a blend of bioactive terpenes with recognized medicinal properties, has been recently shown to exert anti-tumor growth activity through inhibition of cancer cell proliferation, survival, angiogenesis and inflammatory response.
    [Show full text]
  • Dissecting Bcr-Abl Variant Signaling Pathways Using
    DISSECTING BCR-ABL VARIANT SIGNALING PATHWAYS USING NOVEL INTERACTOME IDENTIFICATION STRATEGIES By Jevon A. Cutler A dissertation submitted to The Johns Hopkins University in conformity with the requirement of the degree of Doctor of Philosophy Baltimore, MD May 2018 © 2018 Jevon A. Cutler All Rights Reserved ABSTRACT Cell signaling is an essential function of cells and tissues. Understanding cell signaling necessitates technologies that can identify protein-protein interactions as well as post translational modifications to proteins within protein complexes. The goals of this study are (1) to understand how BCR-ABL variants differentially signal to produce different clinical/experimental phenotypes and (2) to develop novel interactome detection strategies to understand signaling. This dissertation describes an integrated approach of the use of proximity dependent labeling protein-protein interaction analysis assays coupled with global phosphorylation analysis to investigate the differences in signaling between two variants the oncogenic fusion protein, BCR-ABL. Two major types of leukemogenic BCR-ABL fusion proteins are p190BCR-ABL and p210BCR-ABL. Although the two fusion proteins are closely related, they can lead to different clinical outcomes. A thorough understanding of the signaling programs employed by these two fusion proteins is necessary to explain these clinical differences. Our findings suggest that p190BCR-ABL and p210BCR-ABL differentially activate important signaling pathways, such as JAK-STAT, and engage with molecules that indicate interaction with different subcellular compartments. In the case of p210BCR-ABL, we observed an increased engagement of molecules active proximal to the membrane and in the case of p190BCR-ABL, an engagement of molecules of the cytoskeleton.
    [Show full text]
  • Análise Correlacional Entre a Expressão Dos Fatores De Splicing E a Ocorrência De Splicing Alternativo Em Tecidos Humanos E De Camundongos
    ANÁLISE CORRELACIONAL ENTRE A EXPRESSÃO DOS FATORES DE SPLICING E A OCORRÊNCIA DE SPLICING ALTERNATIVO EM TECIDOS HUMANOS E DE CAMUNDONGOS JULIO CÉSAR NUNES Dissertação apresentada à Fundação Antônio Prudente para a obtenção do título de Mestre em Ciências Área de Concentração: Oncologia Orientador: Dr. Sandro José de Souza São Paulo 2008 FICHA CATALOGRÁFICA Preparada pela Biblioteca da Fundação Antônio Prudente Nunes, Julio César Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos / Julio César Nunes – São Paulo, 2008. 79p. Dissertação (Mestrado) - Fundação Antônio Prudente. Curso de Pós-Graduação em Ciências - Área de concentração: Oncologia. Orientador: Sandro José Souza Descritores: 1. SPLICING ALTERNATIVO 2. BIOLOGIA MOLECULAR COMPUTACIONAL 3. CÂNCER 4. GENOMICA. AGRADECIMENTOS Agradeço à FAPESP e CAPES pela bolsa de Mestrado. Ao Sandro José de Souza agradeço toda orientação e conhecimento oferecido. Meus especiais agradecimentos ao Pedro Alexandre Favoretto Galante que dedicou atenção a minha formação no processo de Pós-Graduação na Fundação Antônio Prudente, bem como pela sua oficiosa co-orientação ao projeto de pesquisa. À grande família e amigos pela dedicação e incentivo a minha formação acadêmica. À Fundação Antônio Prudente, Hospital do Câncer e Instituto Ludwig de Pesquisa sobre o Câncer dedico os meus nobres agradecimentos finais. RESUMO Nunes JC. Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos. São Paulo; 2007. [Dissertacão de Mestrado - Fundação Antônio Prudente] Splicing alternativo desempenha uma significante função no aumento da complexidade genômica, produzindo um extenso número de mRNA e isoformas protéicas.
    [Show full text]
  • Dissertation
    DISSERTATION submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences presented by Syafrizayanti born in Padang, Indonesia Oral examination: March 11, 2014 Production of Personalized Protein Microarrays Optimized production of protein microarrays and the establishment of processes for the representation of protein conformations that occur in individual patients Referees: Prof. Dr. Stefan Wiemann Prof. Dr. Stefan Wölfl Thesis declaration I hereby declare that this thesis has been written only by the undersigned and without any assistance from third parties. Furthermore, I confirm that no sources have been used in the preparation of this thesis other than those indicated in the thesis itself. Heidelberg, 2014 Syafrizayanti Part of this work has been accepted for publication: Syafrizayanti, Betzen C, Hoheisel JD, Kastelic D. Methods for analysing and quantifying protein-protein interactions. Exp. Rev. Prot. (2014) in press. Another manuscript will be submitted while this thesis is evaluated: Syafrizayanti, Lueong SS, Hoheisel JD. Production of personalized protein microarrays (2014). Lueong SS, Syafrizayanti, Hoheisel JD. Production of functional protein microarrays from cDNA products and functional applications (2014). Poster presentations Syafrizayanti, Lueong S, Hoheisel JD, Personalised proteomics by means of individualised protein microarrays, HUPO 12th Annual World Congress, Yokohama, September 2013 Bilen S,
    [Show full text]
  • Copyright by Yen-I Grace Chen 2007
    Copyright by Yen-I Grace Chen 2007 The Dissertation Committee for Yen-I Grace Chen Certifies that this is the approved version of the following dissertation: Proteomic Analysis of the Pre-mRNA Splicing Machinery Utilizing Chromosomal Locus Epitope Tagging in Metazoans Committee: Scott Stevens, Supervisor Henry Bose Robert Krug Arlen Johnson David Hoffman Proteomic Analysis of the Pre-mRNA Splicing Machinery Utilizing Chromosomal Locus Epitope Tagging in Metazoans by Yen-I Grace Chen, M.D. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin August, 2007 Dedication To my loving family Acknowledgements I offer sincere thanks to my advisor, Professor Scott Stevens for providing me the opportunity to join his laboratory. His enthusiasm and patience contributed to the success of my research. I also wish to acknowledge professors Robert Krug, Henry Bose, Arlen Johnson, and David Hoffman for serving as my dissertation committee and for their constructive comments and expertise during my dissertation work; professors Phil Tucker and Karen Artzt for helpful conversations, and William Kuziel for plasmids. I would especially thank Shanna Maika and Deb Surman for their persistence and painstaking work in generating our transgenic mice, breeding, and maintenance; Xin Yao and Chad McKee for technical assistance. I also wish to thank all my colleagues in the Stevens lab: Josh Combs, Adam Roth, Champ Gupton, Rea Lardelli, Jennifer Hennigan and former members Dannialle Clayton and Colin Chu, for helpful discussions and establishing a fun environment for research.
    [Show full text]
  • 393LN V 393P 344SQ V 393P Probe Set Entrez Gene
    393LN v 393P 344SQ v 393P Entrez fold fold probe set Gene Gene Symbol Gene cluster Gene Title p-value change p-value change chemokine (C-C motif) ligand 21b /// chemokine (C-C motif) ligand 21a /// chemokine (C-C motif) ligand 21c 1419426_s_at 18829 /// Ccl21b /// Ccl2 1 - up 393 LN only (leucine) 0.0047 9.199837 0.45212 6.847887 nuclear factor of activated T-cells, cytoplasmic, calcineurin- 1447085_s_at 18018 Nfatc1 1 - up 393 LN only dependent 1 0.009048 12.065 0.13718 4.81 RIKEN cDNA 1453647_at 78668 9530059J11Rik1 - up 393 LN only 9530059J11 gene 0.002208 5.482897 0.27642 3.45171 transient receptor potential cation channel, subfamily 1457164_at 277328 Trpa1 1 - up 393 LN only A, member 1 0.000111 9.180344 0.01771 3.048114 regulating synaptic membrane 1422809_at 116838 Rims2 1 - up 393 LN only exocytosis 2 0.001891 8.560424 0.13159 2.980501 glial cell line derived neurotrophic factor family receptor alpha 1433716_x_at 14586 Gfra2 1 - up 393 LN only 2 0.006868 30.88736 0.01066 2.811211 1446936_at --- --- 1 - up 393 LN only --- 0.007695 6.373955 0.11733 2.480287 zinc finger protein 1438742_at 320683 Zfp629 1 - up 393 LN only 629 0.002644 5.231855 0.38124 2.377016 phospholipase A2, 1426019_at 18786 Plaa 1 - up 393 LN only activating protein 0.008657 6.2364 0.12336 2.262117 1445314_at 14009 Etv1 1 - up 393 LN only ets variant gene 1 0.007224 3.643646 0.36434 2.01989 ciliary rootlet coiled- 1427338_at 230872 Crocc 1 - up 393 LN only coil, rootletin 0.002482 7.783242 0.49977 1.794171 expressed sequence 1436585_at 99463 BB182297 1 - up 393
    [Show full text]